{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:15:32Z","timestamp":1790270132090,"version":"4.1.0"},"reference-count":189,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>The impact of diabetic foot (DF) on the healthcare system represents a major public health problem, leading to a considerable clinical and economic burden. The factors contributing to DF\u2019s development and progression are strongly interconnected, including metabolic causes, neuropathy, arteriopathy, and inflammatory changes. Sodium\u2013glucose cotransporter 2 inhibitors (SGLT2-i), novel oral hypoglycemic drugs used as an adjunct to standard treatment, have recently changed the pharmacological management of diabetes. Nevertheless, data about the risk of limb amputation, discordant and limited to canagliflozin, which is currently avoided in the case of peripheral artery disease, have potentially discouraged the design of specific studies targeting DF. There is good evidence for the single immunomodulatory, neuroprotective, and beneficial vascular effects of SGLT2-i. Still, there is no clinical evidence about the early use of SGLT2-i in diabetic foot due to the lack of longitudinal and prospective studies proving the effect of these drugs without confounders. This narrative review aims to discuss the main evidence about the impact of SGLT2-i on the three complications of diabetes implicated in the development of DF, the state of the art, and the potential future implications.<\/jats:p>","DOI":"10.3390\/medicina60111796","type":"journal-article","created":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T11:53:43Z","timestamp":1730462023000},"page":"1796","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives\u2014A Narrative Review"],"prefix":"10.3390","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4797-2523","authenticated-orcid":false,"given":"Giuseppe","family":"Miceli","sequence":"first","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Grazia","family":"Basso","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0782-9922","authenticated-orcid":false,"given":"Andrea Roberta","family":"Pennacchio","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2010-8863","authenticated-orcid":false,"given":"Elena","family":"Cocciola","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pintus","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariagiovanna","family":"Cuffaro","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Profita","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Rizzo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Sferruzza","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6440-7318","authenticated-orcid":false,"given":"Antonino","family":"Tuttolomondo","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (ProMISE), Universit\u00e0 degli Studi di Palermo, Piazza delle Cliniche 2, 90127 Palermo, Italy"},{"name":"Internal Medicine and Stroke Care Ward, University Hospital, Policlinico \u201cP. Giaccone\u201d, 90127 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jcot.2021.01.017","article-title":"The current burden of diabetic foot disease","volume":"17","author":"Edmonds","year":"2021","journal-title":"J. Clin. Orthop. Trauma"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13047-020-00383-2","article-title":"Five year mortality and direct costs of care for people with diabetic foot complications are comparable to cancer","volume":"13","author":"Armstrong","year":"2020","journal-title":"J. Foot Ankle Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/diacare.13.5.513","article-title":"Pathways to diabetic limb amputation: Basis for prevention","volume":"13","author":"Pecoraro","year":"1990","journal-title":"Diabetes Care"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4502","DOI":"10.7150\/thno.54498","article-title":"Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics","volume":"11","author":"Liu","year":"2021","journal-title":"Theranostics"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Xie, L., Xiao, Y., Tai, S., Yang, H., Zhou, S., and Zhou, Z. (2022). Emerging Roles of Sodium Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Cardiovascular Diseases: Focusing on Immunity, Inflammation and Metabolism. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.836849"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R.A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., De Angelis, A., and Sportiello, L. (2022). Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.1008922"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1111\/dom.15571","article-title":"Risk of lower extremity amputation in patients with type 2 diabetes mellitus and peripheral arterial disease receiving sodium-glucose cotransporter-2 inhibitors versus other medications: A systematic review and meta-analysis of observational cohort studies","volume":"26","author":"Hodgson","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/1534734619878090","article-title":"Canagliflozin and Amputation Risk: Evidence So Far","volume":"19","author":"Papadokostaki","year":"2020","journal-title":"Int. J. Low. Extrem. Wounds"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.metabol.2008.01.004","article-title":"Cardiovascular risk profile and morbidity in subjects affected by type 2 diabetes mellitus with and without diabetic foot","volume":"57","author":"Pinto","year":"2008","journal-title":"Metabolism"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/B978-0-444-53480-4.00027-8","article-title":"Mechanisms of disease: Mitochondrial dysfunction in sensory neuropathy and other complications in diabetes","volume":"Volume 126","author":"Fernyhough","year":"2014","journal-title":"Handbook Clinical Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.tips.2006.04.003","article-title":"PKD at the crossroads of DAG and PKC signaling","volume":"27","author":"Wang","year":"2006","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.12968\/jowc.1992.1.1.52","article-title":"Molecular components of the extracellular matrix","volume":"1","author":"Hopkinson","year":"1992","journal-title":"J. Wound Care"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4196\/kjpp.2014.18.1.1","article-title":"Advanced glycation end products and diabetic complications","volume":"18","author":"Singh","year":"2014","journal-title":"Korean J. Physiol. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"52","DOI":"10.2337\/diaclin.27.2.52","article-title":"A Review of the Pathophysiology, Classification, and Treatment of Foot Ulcers in Diabetic Patients","volume":"27","author":"Clayton","year":"2009","journal-title":"Clin. Diabetes"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.avsg.2007.12.012","article-title":"Does diabetes mellitus play a role in restenosis and patency rates follow- ing lower extremity peripheral arterial revascularization? A critical overview","volume":"22","author":"Paraskevas","year":"2008","journal-title":"Ann. Vasc. Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-023-01880-x","article-title":"Metabolic memory in diabetic foot syndrome (DFS): MICRO-RNAS, single nucleotide polymorphisms (SNPs) frequency and their relationship with indices of endothelial function and adipo-inflammatory dysfunction","volume":"22","author":"Pipitone","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-021-01337-z","article-title":"Assessment of heart rate variability (HRV) in subjects with type 2 diabetes mellitus with and without diabetic foot: Correlations with endothelial dysfunction indices and markers of adipo-inflammatory dysfunction","volume":"20","author":"Tuttolomondo","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1055\/a-1493-0458","article-title":"Neuropeptides, Inflammation, Biofilms, and diabetic Foot Ulcers","volume":"130","author":"Yang","year":"2022","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jvs.2006.09.044","article-title":"The adverse effects of race, insurance status, and low income on the rate of amputation in patients presenting with lower extremity ischemia","volume":"45","author":"Eslami","year":"2007","journal-title":"J. Vasc. Surg."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1002\/dmrr.861","article-title":"Advanced glycation end products and diabetic foot disease","volume":"24","author":"Huijberts","year":"2008","journal-title":"Diabetes\/Metabolism Res. Rev."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI118563","article-title":"BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells","volume":"97","author":"Giardino","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2337\/diab.35.9.999","article-title":"Trapped immunoglobulins on peripheral nerve myelin from patients with diabetes mellitus","volume":"35","author":"Brownlee","year":"1986","journal-title":"Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1210\/en.2006-0073","article-title":"Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress","volume":"148","author":"Vincent","year":"2007","journal-title":"Endocrinology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9440(10)61723-3","article-title":"Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice","volume":"159","author":"Goova","year":"2001","journal-title":"Am. J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Vuj\u010di\u0107, S., Kotur-Stevuljevi\u0107, J., Veki\u0107, J., Perovi\u0107-Blagojevi\u0107, I., Stefanovi\u0107, T., Ili\u0107-Mijailovi\u0107, S., Uzelac, B.K., Bosi\u0107, S., Antoni\u0107, T., and Guzonji\u0107, A. (2022). Oxidative Stress and Inflammatory Biomarkers in Patients with Diabetic Foot. Medicina, 58.","DOI":"10.3390\/medicina58121866"},{"key":"ref_26","first-page":"86","article-title":"Neutrophil to Lymphocyte ratio is significantly reduced after Sodium glucose cotransporter-2 inhibitor treatment in patients with type 2 diabetes mellitus","volume":"18","author":"Kurtkulagi","year":"2022","journal-title":"Int. J. Endocrinol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1086\/383267","article-title":"Diagnosing foot infection in diabetes","volume":"39","author":"Williams","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00592-019-01301-0","article-title":"The prevalence of methicillin-resistant Staphylococcus aureus among diabetic patients: A meta-analysis","volume":"56","author":"Stacey","year":"2019","journal-title":"Acta Diabetol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ijid.2018.02.013","article-title":"Influence of multidrug resistant organisms on the outcome of diabetic foot infection","volume":"70","author":"Saltoglu","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1113\/jphysiol.2005.095042","article-title":"Kv4 potassium channel subunits control action potential repolarization and frequency-dependent broadening in rat hippocampal CA1 pyramidal neurones","volume":"569","author":"Kim","year":"2005","journal-title":"J. Physiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1056\/NEJMcp032966","article-title":"Clinical practice. Neuropathic diabetic foot ulcers","volume":"351","author":"Boulton","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12223-023-01119-y","article-title":"Gut microbiota in relationship to diabetes mellitus and its late complications with a focus on diabetic foot syndrome: A review","volume":"69","author":"Mahayri","year":"2024","journal-title":"Folia Microbiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(18)32590-X","article-title":"SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: A systematic review and meta-analysis of cardiovascular outcome trials","volume":"393","author":"Zelniker","year":"2019","journal-title":"Lancet"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_35","first-page":"2646","article-title":"Novel Diabetes Drugs and the Cardiovascular Specialist","volume":"69","author":"Sattar","year":"2017","journal-title":"Circ."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1111\/dom.12970","article-title":"Sodium-glucose co-transporter (SGLT)2 and SGLT1 renal expression in patients with type 2 diabetes","volume":"19","author":"Solini","year":"2017","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.2337\/dc13-0387","article-title":"Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes","volume":"36","author":"DeFronzo","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30\u201350% of filtered glucose load in humans","volume":"62","author":"DeFronzo","year":"2013","journal-title":"Diabetes"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1161\/CIRCULATIONAHA.117.030418","article-title":"Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus with That of Heart Failure","volume":"136","author":"Packer","year":"2017","journal-title":"Circulation"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1210\/jc.2014-3472","article-title":"Dapagliflozin lowers plasma glucose concentration and improves \u03b2-Cell function","volume":"100","author":"Merovci","year":"2015","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1210\/jc.2017-01838","article-title":"Empagliflozin Treatment is Associated with Improved Beta Cell Function in T2DM","volume":"103","author":"Daniele","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1182\/asheducation-2005.1.436","article-title":"Pathogenesis of Atherosclerosis","volume":"2005","author":"Crowther","year":"2005","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019: Update from the GBD 2019 study","volume":"76","author":"Roth","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","article-title":"Cardiovascular disease in type 2 diabetes mellitus: Progress toward personalized management","volume":"21","author":"Ma","year":"2022","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_45","first-page":"45","article-title":"Type 2 diabetes mellitus, oxidative stress and inflammation: Examining the links","volume":"11","author":"Oguntibeju","year":"2019","journal-title":"Int. J. Physiol. Pathophysiol. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s00125-016-4158-2","article-title":"The Beneficial Effects of Empagliflozin, an SGLT2 inhibitor, on Atherosclerosis in ApoE\u2212\/\u2212Mice Fed a Western Diet","volume":"60","author":"Han","year":"2017","journal-title":"Diabetologia"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"110487","DOI":"10.1016\/j.mce.2019.110487","article-title":"Empagliflozin improves primary haemodynamic parameters and attenuates the development of atherosclerosis in high fat diet fed APOE knockout mice","volume":"494","author":"Dimitriadis","year":"2019","journal-title":"Mol. Cell. Endocrinol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"173040","DOI":"10.1016\/j.ejphar.2020.173040","article-title":"Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice","volume":"875","author":"Ganbaatar","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12944-021-01430-y","article-title":"Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity","volume":"20","author":"Liu","year":"2021","journal-title":"Lipids Heal. Dis."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"de Mortanges, A.P., Salvador, D., Laimer, M., Muka, T., Wilhelm, M., and Bano, A. (2021). The role of SGLT2 inhibitors in atherosclerosis: A narrative mini-review. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.751214"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose Co-transporter 2 (SGLT2) inhibitors: A state-of-the-Art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12933-018-0750-8","article-title":"Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury","volume":"17","author":"Aroor","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12967-019-1881-8","article-title":"Acute canagliflozin treatment protects against in vivo myocardial ischemia-reperfusion injury in non-diabetic male rats and enhances endothelium-dependent vasorelaxation","volume":"17","author":"Sayour","year":"2019","journal-title":"J. Trans. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"865","DOI":"10.33594\/000000178","article-title":"Empagliflozin and Dapagliflozin Reduce ROS Generation and Restore NO Bioavailability in Tumor Necrosis Factor \u03b1-Stimulated Human Coronary Arterial Endothelial Cells","volume":"53","author":"Uthman","year":"2019","journal-title":"Cell Physiol. Biochem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1002\/biof.1052","article-title":"Triglyceride accumulation in macrophages upregulates paraoxonase 2 (PON2) expression via ROS-mediated JNK\/c-Jun signaling pathway activation","volume":"38","author":"Rosenblat","year":"2012","journal-title":"BioFactors"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.vph.2012.03.005","article-title":"Role of oxidative stress in diabetes-mediated vascular dysfunction: Unifying hypothesis of diabetes revisited","volume":"57","author":"Schaffer","year":"2012","journal-title":"Vasc. Pharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12933-021-01252-3","article-title":"Angiotensin II-induced upregulation of SGLT1 and 2 contributes to human microparticle-stimulated endothelial senescence and dysfunction: Protective effect of gliflozins","volume":"20","author":"Park","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.5551\/jat.52100","article-title":"Canagliflozin Prevents Diabetes-Induced Vascular Dysfunction in ApoE-Deficient Mice","volume":"27","author":"Rahadian","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.vph.2018.06.006","article-title":"Hyperglycaemic impairment of PAR2-mediated vasodilation: Prevention by inhibition of aortic endothelial sodium-glucose-co-Transporter-2 and minimizing oxidative stress","volume":"109","author":"Venu","year":"2018","journal-title":"Vasc. Pharmacol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12933-018-0749-1","article-title":"Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice","volume":"17","author":"Dimitriadis","year":"2018","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Nakatsu, Y., Kokubo, H., Bumdelger, B., Yoshizumi, M., Yamamotoya, T., Matsunaga, Y., Ueda, K., Inoue, Y., Inoue, M.-K., and Fujishiro, M. (2017). The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081704"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1161\/CIRCULATIONAHA.113.003199","article-title":"Targeting Interleukin-1 in heart disease","volume":"128","author":"Toldo","year":"2013","journal-title":"Circulation"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Shao, B.-Z., Xu, Z.-Q., Han, B.-Z., Su, D.-F., and Liu, C. (2015). NLRP3 inflammasome and its inhibitors: A review. Front. Pharmacol., 6.","DOI":"10.3389\/fphar.2015.00262"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"507208","DOI":"10.1155\/2014\/507208","article-title":"Silence of NLRP3 suppresses atherosclerosis and stabilizes plaques in apolipoprotein E-deficient mice","volume":"2014","author":"Zheng","year":"2014","journal-title":"Mediat. Inflamm."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e003031","DOI":"10.1161\/JAHA.115.003031","article-title":"NLRP3 inflammasome expression and activation in human atherosclerosis","volume":"5","author":"Varghese","year":"2016","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.hlc.2013.01.012","article-title":"NLRP3 inflammasomes show high expression in aorta of patients with atherosclerosis","volume":"22","author":"Zheng","year":"2013","journal-title":"Hear. Lung Circ."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"6305735","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic apoe\u2212\/\u2212mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediat. Inflamm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"109825","DOI":"10.1016\/j.cellsig.2020.109825","article-title":"The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2\/ROS\/NLRP3\/Caspase-1-dependent IL-1\u03b2 and IL-18 secretion","volume":"77","author":"Sukhanov","year":"2021","journal-title":"Cell Signal."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.drudis.2018.08.005","article-title":"Effects of antidiabetic drugs on NLRP3 inflammasome activity, with a focus on diabetic kidneys","volume":"24","author":"Yaribeygi","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10557-017-6725-2","article-title":"SGLT-2 Inhibition with Dapagliflozin Reduces the Activation of the Nlrp3\/ASC Inflammasome and Attenuates the Development of Diabetic Cardiomyopathy in Mice with Type 2 Diabetes. Further Augmentation of the Effects with Saxagliptin, a DPP4 Inhibitor","volume":"31","author":"Ye","year":"2017","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/nature09663","article-title":"A role for mitochondria in NLRP3 inflammasome activation","volume":"469","author":"Zhou","year":"2011","journal-title":"Nature"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Xu, J., Kitada, M., Ogura, Y., Liu, H., and Koya, D. (2021). Dapagliflozin Restores Impaired Autophagy and Suppresses Inflammation in High Glucose-Treated HK-2 Cells. Cells, 10.","DOI":"10.3390\/cells10061457"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1093\/abbs\/gmz098","article-title":"Interaction between autophagy and the NLRP3 inflammasome","volume":"51","author":"Cao","year":"2019","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Ren, C., Sun, K., Zhang, Y., Hu, Y., Hu, B., Zhao, J., He, Z., Ding, R., Wang, W., and Liang, C. (2021). Sodium-Glucose CoTransporter-2 Inhibitor Empagliflozin Ameliorates Sunitinib-Induced Cardiac Dysfunction via Regulation of AMPK-mTOR Signaling Pathway-Mediated Autophagy. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.664181"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Arag\u00f3n-Herrera, A., Feij\u00f3o-Band\u00edn, S., Santiago, M.O., Barral, L., Campos-Toimil, M., Gil-Longo, J., Pereira, T.M.C., Garc\u00eda-Caballero, T., Rodr\u00edguez-Segade, S., and Rodr\u00edguez, J. (2019). Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats. Biochem. Pharmacol., 170.","DOI":"10.1016\/j.bcp.2019.113677"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"6424","DOI":"10.1002\/jcp.30316","article-title":"Dapagliflozin ameliorates pancreatic injury and activates kidney autophagy by modulating the AMPK\/mTOR signaling pathway in obese rats","volume":"236","author":"Jaikumkao","year":"2021","journal-title":"J. Cell Physiol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/1440-1681.13261","article-title":"Sodium-glucose co-transporters and diabetic nephropathy: Is there a link with toll-like receptors?","volume":"47","author":"Jigheh","year":"2020","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_79","first-page":"1642","article-title":"Effects of Tianxiangdan Granule treatment on atherosclerosis via NF-\u03baB and p38 MAPK signaling pathways","volume":"17","author":"Sun","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"174715","DOI":"10.1016\/j.ejphar.2021.174715","article-title":"Dapagliflozin exerts anti-inflammatory effects via inhibition of LPS-induced TLR-4 overexpression and NF-\u03baB activation in human endothelial cells and differentiated macrophages","volume":"918","author":"Abdollahi","year":"2022","journal-title":"Eur. J. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: Clinical physiology","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yamanashi, T., Iwata, M., Kamiya, N., Tsunetomi, K., Kajitani, N., Wada, N., Iitsuka, T., Yamauchi, T., Miura, A., and Pu, S. (2017). Beta-hydroxybutyrate, an endogenic NLRP3 inflammasome inhibitor, attenuates stress-induced behavioral and inflammatory responses. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-08055-1"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1749-6632.2000.tb06651.x","article-title":"Inflamm-aging: An evolutionary perspective on immunosenescence","volume":"908","author":"Franceschi","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tem.2016.09.005","article-title":"Inflammaging and Garb-aging","volume":"28","author":"Franceschi","year":"2017","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Sch\u00f6nberger, E., Mihaljevi\u0107, V., Steiner, K., \u0160ari\u0107, S., Kurevija, T., Majnari\u0107, L.T., \u0106ur\u010di\u0107, I.B., and Canecki-Var\u017ei\u0107, S. (2023). Immunomodulatory effects of SGLT2 inhibitors\u2014Targeting inflammation and oxidative stress in aging. Int. J. Environ. Res. Public Health, 20.","DOI":"10.3390\/ijerph20176671"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00018-022-04289-z","article-title":"Anti-inflammatory effect of SGLT-2 inhibitors via uric acid and insulin","volume":"79","author":"Olivieri","year":"2022","journal-title":"Cell Mol. Life Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Yu, M., Zhang, H., Wang, B., Zhang, Y., Zheng, X., Shao, B., Zhuge, Q., and Jin, K. (2021). Key Signaling Pathways in Aging and Potential Interventions for Healthy Aging. Cells, 10.","DOI":"10.3390\/cells10030660"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Ji, G., Zhang, Y., Yang, Q., Cheng, S., Hao, J., Zhao, X., and Jiang, Z. (2012). Genistein suppresses LPS-induced inflammatory response through inhibiting NF-\u03baB following AMP kinase activation in RAW 264.7 macrophages. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0053101"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1111\/acel.12689","article-title":"TOR-mediated regulation of metabolism in aging","volume":"16","author":"Antikainen","year":"2017","journal-title":"Aging Cell"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/s41422-020-0301-1","article-title":"Signaling networks in immunometabolism","volume":"30","author":"Saravia","year":"2020","journal-title":"Cell Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"107954","DOI":"10.1016\/j.celrep.2020.107954","article-title":"Proximal Tubule mTORC1 Is a Central Player in the Pathophysiology of Diabetic Nephropathy and Its Correction by SGLT2 Inhibitors","volume":"32","author":"Hinden","year":"2020","journal-title":"Cell Rep."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41420-021-00801-9","article-title":"Canagliflozin protects against cisplatin-induced acute kidney injury by AMPK-mediated autophagy in renal proximal tubular cells","volume":"8","author":"Park","year":"2022","journal-title":"Cell Death Discov."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/1440-1681.13638","article-title":"Dapagliflozin attenuates high glucose-induced endothelial cell apoptosis and inflammation through AMPK\/SIRT1 activation","volume":"49","author":"Faridvand","year":"2022","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e007197","DOI":"10.1161\/CIRCHEARTFAILURE.120.007197","article-title":"Cardioprotective effects of Sirtuin-1 and its downstream effectors: Potential role in mediating the heart failure benefits of SGLT2 (sodium-glucose cotransporter 2) inhibitors","volume":"13","author":"Packer","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.07.048","article-title":"Empagliflozin inhibits macrophage inflammation through AMPK signaling pathway and plays an anti-atherosclerosis role","volume":"367","author":"Fu","year":"2022","journal-title":"Int. J. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e12950","DOI":"10.1111\/acel.12950","article-title":"Targeting senescent cells alleviates obesity-induced metabolicm dysfunction","volume":"18","author":"Palmer","year":"2019","journal-title":"Aging Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e12997","DOI":"10.7554\/eLife.12997","article-title":"Targeting senescent cells enhances adipogenesis and metabolic function in old age","volume":"4","author":"Xu","year":"2015","journal-title":"eLife"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Eleftheriadis, T., Pissas, G., Filippidis, G., Efthymiadi, M., Liakopoulos, V., and Stefanidis, I. (2022). Dapagliflozin Prevents High-Glucose-Induced Cellular Senescence in Renal Tubular Epithelial Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232416107"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1038\/s43587-024-00642-y","article-title":"SGLT2 inhibition eliminates senescent cells and alleviates pathological aging","volume":"4","author":"Katsuumi","year":"2024","journal-title":"Nat. Aging"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41586-021-03547-7","article-title":"An aged immune system drives senescence and ageing of solid organs","volume":"594","author":"Yousefzadeh","year":"2021","journal-title":"Nature"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/s41586-022-05388-4","article-title":"Blocking PD-L1\u2013PD-1 improves senescence surveillance and ageing phenotypes","volume":"611","author":"Wang","year":"2022","journal-title":"Nature"},{"key":"ref_102","first-page":"7","article-title":"Mitochondria in Cell Senescence: Is Mitophagy the Weakest Link?","volume":"21","author":"Korolchuk","year":"2017","journal-title":"E Bio. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/j.1582-4934.2009.00897.x","article-title":"Chemical and molecular mechanisms of antioxidants: Experimental approaches and model systems","volume":"14","author":"Lin","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_104","first-page":"53","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors and Mitochondrial Functions: State of the Art","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"EXCLI J."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Chowdhury, F.I., Nayan, S.I., Rahman, M., Khan, F., and Subhan, N. (2020). Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci. Rep., 10.","DOI":"10.1038\/s41598-020-71449-1"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Pignatelli, P., Baratta, F., Buzzetti, R., D\u2019amico, A., Castellani, V., Bartimoccia, S., Siena, A., D\u2019onofrio, L., Maddaloni, E., and Pingitore, A. (2022). The Sodium\u2013Glucose Co-Transporter-2 (SGLT2) Inhibitors Reduce Platelet Activation and Thrombus Formation by Lowering NOX2-Related Oxidative Stress: A Pilot Study. Antioxidants, 11.","DOI":"10.3390\/antiox11101878"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Gager, G.M., von Lewinski, D., Sourij, H., Jilma, B., Eyileten, C., Filipiak, K., H\u00fclsmann, M., Kubica, J., Postula, M., and Siller-Matula, J.M. (2021). Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. Biomed. Pharmacother., 143.","DOI":"10.1016\/j.biopha.2021.112169"},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Hodrea, J., Saeed, A., Molnar, A., Fintha, A., Barczi, A., Wagner, L.J., Szabo, A.J., Fekete, A., and Balogh, D.B. (2022). SGLT2 inhibitor dapagliflozin prevents atherosclerotic and cardiac complications in experimental type 1 diabetes. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0263285"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12933-020-01206-1","article-title":"Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: Prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial","volume":"20","author":"Katakami","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12933-023-01879-4","article-title":"Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: A 2-year extension study of the UTOPIA trial","volume":"22","author":"Katakami","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e015716","DOI":"10.1161\/JAHA.119.015716","article-title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment","volume":"9","author":"Ikonomidis","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Kourtidou, C., Rafailidis, V., Varouktsi, G., Kanakis, E., Liakopoulos, V., Vyzantiadis, T.-A., Savopoulos, C., Marinaki, S., Stangou, M., and Tziomalos, K. (2023). Effects of Sodium-Glucose Co-Transporter-2 Inhibitors on Markers of Vascular Damage. J. Pers. Med., 13.","DOI":"10.3390\/jpm13030536"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"e022761","DOI":"10.1161\/JAHA.121.022761","article-title":"Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability","volume":"11","author":"Chen","year":"2022","journal-title":"J. Am. Hear. Assoc."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12933-023-01814-7","article-title":"SGLT2-inhibitors effects on the coronary fibrous cap thickness and MACEs in diabetic patients with inducible myocardial ischemia and multi vessels non-obstructive coronary artery stenosis","volume":"22","author":"Sardu","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12272-022-01391-5","article-title":"Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: A glucose-independent effect through AMPK signaling","volume":"45","author":"Abdelkader","year":"2022","journal-title":"Arch. Pharmacal Res."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1016\/j.lfs.2004.01.007","article-title":"MAPK activation in nociceptive neurons and pain hypersensitivity","volume":"74","author":"Obata","year":"2004","journal-title":"Life Sci."},{"key":"ref_118","first-page":"257","article-title":"Targeting AMPK for the alleviation of pathological pain","volume":"Volume 107","author":"Asiedu","year":"2016","journal-title":"Structure and Regulation of AMPK"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1744-8069-3-33","article-title":"p38 MAPK, Microglial Signaling, and Neuropathic Pain","volume":"3","author":"Ji","year":"2007","journal-title":"Mol. Pain"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1021\/acschemneuro.8b00680","article-title":"Contributions of mTOR Activation-Mediated Upregulation of Synapsin II and Neurite Outgrowth to Hyperalgesia in STZ-Induced Diabetic Rats","volume":"10","author":"He","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jchemneu.2017.12.011","article-title":"Lycium barbarum polysaccharide protects diabetic peripheral neuropathy by enhancing autophagy via mTOR\/p70S6K inhibition in Streptozotocin-induced diabetic rats","volume":"89","author":"Liu","year":"2018","journal-title":"J. Chem. Neuroanat."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ncb2757","article-title":"ULK1 induces autophagy by phosphorylating Beclin-1 and activating VPS34 lipid kinase","volume":"15","author":"Russell","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/jnc.14336","article-title":"Liraglutide ameliorated peripheral neuropathy in diabetic rats: Involvement of oxidative stress, inflammation and extracellular matrix remodeling","volume":"146","author":"Moustafa","year":"2018","journal-title":"J. Neurochem."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Karl, F., Grie\u00dfhammer, A., \u00dc\u00e7eyler, N., and Sommer, C. (2017). Differential Impact of miR-21 on Pain and Associated Affective and Cognitive Behavior after Spared Nerve Injury in B7-H1 ko Mouse. Front. Mol. Neurosci., 10.","DOI":"10.3389\/fnmol.2017.00219"},{"key":"ref_125","first-page":"2211","article-title":"Effect of Dapagliflozin Combined with Mecobalamin on Blood Glucose Concentration and Serum Mda, Sod, And Cox-2 In Patients with Type 2 Diabetes Mellitus Complicated With Peripheral Neuropathy","volume":"35","author":"Wang","year":"2019","journal-title":"Acta Medica. Mediterr."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Pawlos, A., Broncel, M., Wo\u017aniak, E., and Gorzelak-Pabi\u015b, P. (2021). Effetto neuroprotettivo degli inibitori SGLT2. Molecole, 26.","DOI":"10.3390\/molecules26237213"},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Restrepo, B.I., Twahirwa, M., Rahbar, M.H., and Schlesinger, L.S. (2014). Phagocytosis via Complement or Fc-Gamma Receptors Is Compromised in Monocytes from Type 2 Diabetes Patients with Chronic Hyperglycemia. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0092977"},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Berrou, J., Fougeray, S., Venot, M., Chardiny, V., Gautier, J.-F., Dulphy, N., Toubert, A., and Peraldi, M.-N. (2013). Natural Killer Cell Function, an Important Target for Infection and Tumor Protection, Is Impaired in Type 2 Diabetes. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0062418"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.febslet.2013.05.053","article-title":"High glucose modulates IL-6 mediated immune homeostasis through impeding neutrophil extracellular trap formation","volume":"587","author":"Joshi","year":"2013","journal-title":"FEBS Lett."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Kumar, A.U., Zan, M.A., Ng, C.-L., Chieng, S., and Nathan, S. (2024). Diabetes and Infectious Diseases with a Focus on Melioidosis. Curr. Microbiol., 81.","DOI":"10.1007\/s00284-024-03748-z"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1182\/bloodadvances.2023012403","article-title":"Neutrophil functions in patients with neutropenia due to glycogen storage disease type 1b treated with empagliflozin","volume":"8","author":"Kaczor","year":"2024","journal-title":"Blood Adv."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/jimd.12509","article-title":"Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5","volume":"45","author":"Boulanger","year":"2022","journal-title":"J. Inherit. Metab. Dis."},{"key":"ref_133","first-page":"442","article-title":"Type 2 Diabetes and its Impact on the Immune System","volume":"16","author":"Berbudi","year":"2020","journal-title":"Curr. Diabetes Rev."},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Nirenjen, S., Narayanan, J., Tamilanban, T., Subramaniyan, V., Chitra, V., Fuloria, N.K., Wong, L.S., Ramachawolran, G., Sekar, M., and Gupta, G. (2023). Exploring the contribution of pro-inflammatory cytokines to impaired wound healing in diabetes. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1216321"},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Lin, C., Liu, J., and Sun, H. (2020). Risk factors for lower extremity amputation in patients with diabetic foot ulcers: A meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0239236"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e2202751","DOI":"10.1002\/adhm.202202751","article-title":"Dapagliflozin-Loaded Exosome Mimetics Facilitate Diabetic Wound Healing by HIF-1\u03b1-Mediated Enhancement of Angiogenesis","volume":"12","author":"Zhang","year":"2022","journal-title":"Adv. Health Mater."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jce.16344","article-title":"SGLT2i effect on atrial fibrillation: A network meta-analysis of randomized controlled trials","volume":"35","author":"Mariani","year":"2024","journal-title":"J. Cardiovasc. Electrophysiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.clnesp.2024.07.016","article-title":"Effect of sodium glucose Co-transporter 2 inhibitor use on anthropometric measurements and blood glucose in obese and non-obese type 2 diabetic patients","volume":"63","author":"Dedemen","year":"2024","journal-title":"Clin. Nutr. ESPEN"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ebiom.2017.05.028","article-title":"SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice","volume":"20","author":"Xu","year":"2017","journal-title":"EBioMedicine"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.cmet.2023.05.001","article-title":"Canagliflozin impairs T cell effector function via metabolic suppression in autoimmunity","volume":"35","author":"Jenkins","year":"2023","journal-title":"Cell Metab."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.18293","article-title":"Empagliflozin modulates CD4+ T-cell differentiation via metabolic reprogramming in immune thrombocytopenia","volume":"198","author":"Qin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_142","first-page":"583","article-title":"L\u2019ETUDE CLINIQUE DU MOIS EMPA-REG OUTCOME: L\u2019empagliflozine r\u00e9duit la mortalit\u00e9 chez le patient diab\u00e9tique de type 2 \u00e0 haut risque cardiovasculaire [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk]","volume":"70","author":"Scheen","year":"2015","journal-title":"Rev. Med. Liege."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1186\/s12933-023-01992-4","article-title":"Sodium-glucose co-transporter 2 inhibitor use in patients with diabetes mellitus undergoing endovascular therapy for symptomatic peripheral artery disease","volume":"22","author":"Takahara","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Mavrakanas, T.A., Tsoukas, M.A., Brophy, J.M., Sharma, A., and Gariani, K. (2023). SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: A systematic review and meta-analysis. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-42989-z"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-020-01118-0","article-title":"Major adverse cardiovascular and limb events in patients with diabetes and concomitant peripheral artery disease treated with sodium glucose cotransporter 2 inhibitor versus dipeptidyl peptidase-4 inhibitor","volume":"19","author":"Lee","year":"2020","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1177\/1358863X221143811","article-title":"Effects of SGLT2 inhibitors and GLP1-receptor agonists on cardiovascular and limb events in peripheral artery disease: A review","volume":"28","author":"Skeik","year":"2023","journal-title":"Vasc. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12933-021-01306-6","article-title":"SGLT2 inhibitors and lower limb complications: An updated meta-analysis","volume":"20","author":"Lin","year":"2021","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12933-023-01789-5","article-title":"Neutral effects of SGLT2 inhibitors in acute coronary syndromes, peripheral arterial occlusive disease, or ischemic stroke: A meta-analysis of randomized controlled trials","volume":"22","author":"Tsai","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1177\/1358863X221101653","article-title":"Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials","volume":"27","author":"Patoulias","year":"2022","journal-title":"Vasc. Med."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s10557-021-07254-3","article-title":"Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure","volume":"36","author":"Correale","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"248","DOI":"10.7326\/M18-3136","article-title":"Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study","volume":"171","author":"Dave","year":"2019","journal-title":"Ann. Intern. Med."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Chen, L., Xue, Q., Yan, C., Tang, B., Wang, L., Zhang, B., and Zhao, Q. (2023). Comparative safety of different recommended doses of sodium\u2013glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis of randomized clinical trials. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1256548"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s00592-018-1116-0","article-title":"SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials","volume":"55","author":"Puckrin","year":"2018","journal-title":"Acta Diabetol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/dom.12825","article-title":"Urinary tract and genital infections in patients with type 2 diabetes treated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of randomized controlled trials","volume":"19","author":"Li","year":"2016","journal-title":"Diabetes Obes. Metab."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4081\/aiua.2023.11509","article-title":"Risk of urogenital infections in non-diabetic patients treated with sodium glucose transporter 2 (SGLT2) inhibitors. Systematic review and meta-analysis","volume":"95","author":"Bapir","year":"2023","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"k4365","DOI":"10.1136\/bmj.k4365","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: Nationwide register based cohort study","volume":"363","author":"Ueda","year":"2018","journal-title":"BMJ"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1111\/dom.13820","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of genital mycotic and urinary tract infection: A population-based study of older women and men with diabetes","volume":"21","author":"Lega","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40261-023-01256-9","article-title":"Risk of Urinary Tract Infection in Patients with Type 2 Diabetes Mellitus Treated with Dapagliflozin: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"43","author":"Zheng","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Liu, H. (2024). Case literature analysis of Fournier\u2019s gangrene caused by sodium-glucose protein-2 inhibitors. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1301105"},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Ishibashi, F., Kosaka, A., and Tavakoli, M. (2022). Sodium Glucose Cotransporter-2 Inhibitor Protects Against Diabetic Neuropathy and Nephropathy in Modestly Controlled Type 2 Diabetes: Follow-Up Study. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.864332"},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Kandeel, M. (2022). The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.926717"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/dom.13115","article-title":"Risk of lower extremity amputations in people with type 2 diabetes mellitus treated with sodium-glucose co-transporter-2 inhibitors in the USA: A retrospective cohort study","volume":"20","author":"Yuan","year":"2017","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1093\/cid\/cis346","article-title":"2012 Infectious Diseases Society of America Clinical Practice Guideline for the Diagnosis and Treatment of Diabetic Foot Infectionsa","volume":"54","author":"Lipsky","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"ref_166","first-page":"CD011038","article-title":"Topical antimicrobial agents for treating foot ulcers in people with diabetes","volume":"6","author":"Dumville","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Heyward, J., Mansour, O., Olson, L., Singh, S., and Alexander, G.C. (2020). Association between sodium-glucose cotransporter 2 (SGLT2) inhibitors and lower extremity amputation: A systematic review and meta-analysis. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0234065"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13647","article-title":"Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers","volume":"21","author":"Yang","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pds.932","article-title":"Antihypertensive drug therapy and the risk of lower extremity amputations in pharmacologically treated type 2 diabetes patients","volume":"13","author":"Erkens","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12933-023-01897-2","article-title":"The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: A nation-wide cohort study","volume":"22","author":"Werkman","year":"2023","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40261-018-0731-4","article-title":"Effects of Sodium-glucose Cotransporter 2 Inhibitors on Amputation, Bone Fracture, and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus Using an Alternative Measure to the Hazard Ratio","volume":"39","author":"Kaneko","year":"2018","journal-title":"Clin. Drug Investig."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1001\/jamainternmed.2018.3034","article-title":"Association Between Sodium-Glucose Cotransporter 2 Inhibitors and Lower Extremity Amputation Among Patients with Type 2 Diabetes","volume":"178","author":"Chang","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.metabol.2019.04.008","article-title":"Sodium-glucose co-transporter-2 inhibitors (SGLT2i) use and risk of amputation: An expert panel overview of the evidence","volume":"96","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"m2812","DOI":"10.1136\/bmj.m2812","article-title":"Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: Cohort study","volume":"370","author":"Fralick","year":"2020","journal-title":"BMJ"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"108113","DOI":"10.1016\/j.diabres.2020.108113","article-title":"Long term outcomes after incident diabetic foot ulcer: Multicenter large cohort prospective study (EDI-FOCUS investigators) epidemiology of diabetic foot complications study","volume":"162","author":"Rastogi","year":"2020","journal-title":"Diabetes Res. Clin. Pract."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/iwj.12119","article-title":"Effective management of patients with diabetes foot ulcers: Outcomes of an interprofessional diabetes foot ulcer team","volume":"12","author":"Ogrin","year":"2013","journal-title":"Int. Wound J."},{"key":"ref_177","first-page":"6429575","article-title":"Healing of diabetic foot ulcers in patients treated at the copenhagen wound healing center in 1999\/2000 and in 2011\/2012","volume":"2019","author":"Jansen","year":"2019","journal-title":"J. Diabetes Res."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12933-017-0611-x","article-title":"Increased amputation risk with canagliflozin treat- ment: Behind the large cardiovascular benefit?","volume":"16","author":"Tanaka","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/jdi.12625","article-title":"Comparisons of weight changes between sodium-glucose cotransporter 2 inhibitors treatment and glucagon-like peptide-1 analogs treatment in type 2 diabetes patients: A meta-analysis","volume":"8","author":"Cai","year":"2017","journal-title":"J. Diabetes Investig."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"826","DOI":"10.2337\/dc20-1464","article-title":"Comparative effectiveness and safety of sodium-glucose cotransporter 2 inhibitors versus glucagon-like pep- tide 1 receptor agonists in older adults","volume":"44","author":"Patorno","year":"2021","journal-title":"Diabetes Care"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1124\/jpet.116.232025","article-title":"Interaction of the sodium\/glucose cotransporter (SGLT) 2 inhibitor canagliflozin with SGLT1 and SGLT2: Inhibition kinetics, sidedness of action, and transporter-associated incorporation accounting for its pharmacodynamic and pharmacokinetic features","volume":"358","author":"Ohgaki","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/dme.13645","article-title":"Sotagliflozin: A dual sodium- glucose co-transporter-1 and -2 inhibitor for the management of type 1 and type 2 diabetes mellitus","volume":"35","author":"Sims","year":"2018","journal-title":"Diabet Med."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Nani, A., Carrara, F., Paulesu, C.M.E., Fratte, C.D., Padroni, M., Enisci, S., Bilancio, M.C., Romio, M.S., Bertuzzi, F., and Pintaudi, B. (2023). Association of Sodium-Glucose Cotransporter 2 Inhibitors with Osteomyelitis and Other Lower Limb Safety Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. J. Clin. Med., 12.","DOI":"10.3390\/jcm12123958"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1007\/s00125-022-05772-9","article-title":"Major adverse cardiovascular and limb events in people with diabetes treated with GLP-1 receptor agonists vs SGLT2 inhibitors","volume":"65","author":"Lin","year":"2022","journal-title":"Diabetologia"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1001\/jamainternmed.2022.6664","article-title":"Comparing Effectiveness and Safety of SGLT2 Inhibitors vs DPP-4 Inhibitors in Patients with Type 2 Diabetes and Varying Baseline HbA1cLevels","volume":"183","author":"Wexler","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/dom.14593","article-title":"Effectiveness and safety of empagliflozin in routine care patients: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study","volume":"24","author":"Patorno","year":"2021","journal-title":"Diabetes, Obes. Metab."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1093\/eurheartj\/ehaa956","article-title":"The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: Real-world study","volume":"42","author":"Paul","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.eprac.2024.01.016","article-title":"Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Hospitalization for Heart Failure and Amputation Rate Compared with Incretin-Based Therapy in Patients with Diabetic Foot Disease: A Nationwide Population-Based Study","volume":"30","author":"Lin","year":"2024","journal-title":"Endocr. Pract."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1796\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:26:58Z","timestamp":1760113618000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/60\/11\/1796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,1]]},"references-count":189,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["medicina60111796"],"URL":"https:\/\/doi.org\/10.3390\/medicina60111796","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,1]]}}}